Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma
Completed
- Conditions
- Cancer of Liver
- Interventions
- Other: No intervention
- Registration Number
- NCT05907772
- Lead Sponsor
- Zhejiang University
- Brief Summary
This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 522
Inclusion Criteria
- The HCC patients received LT with pre-operative PIVKA-II records performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.
Exclusion Criteria
- (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Recipients with preoperative PIVKA-II>240mAU/mL No intervention - Recipients with preoperative PIVKA-II≤240mAU/mL No intervention -
- Primary Outcome Measures
Name Time Method Overall survival January 2015 to December 2020 the overall survival of liver transplant recipient with HCC
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China